NASDAQ Biotechnology NTR Stock

Index

Market Closed - Nasdaq 05:16:03 2024-05-10 pm EDT			5-day change	1st Jan Change
1,349 ^PTS	-0.85%		-1.09%	-0.77%

Current month	+4.03%
1 month	+1.61%

Duration

Period

Style

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM BBIO	May. 11	PU
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO AKRO	May. 10	PR
EXAI Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Exscientia plc EXAI	May. 10	BU
AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc. AKRO	May. 10	BU
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc. AKRO	May. 10	PR
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIRM	May. 10	BU
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EOLS	May. 10	BU
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off INBX	May. 10	PR
Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. EOLS	May. 10	CI
Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. EOLS	May. 10	CI

No results for this search

Date	Price	Change
24-05-10	1,349	-0.85%
24-05-09	1,360	+0.29%
24-05-08	1,356	-0.56%
24-05-07	1,364	+0.21%
24-05-06	1,361	-0.19%

Real-time Nasdaq

Last update May 10, 2024 at 05:16 pm EDT

Indices: Europe's banking sector is in good shape

May 03, 2024 at 04:52 am EDT

The sharpest declines in .
ANAPTYSBIO, INC.	-10.75%
COLLEGIUM PHARMACEUTICAL, INC.	-16.80%
IOVANCE BIOTHERAPEUTICS, INC.	-18.48%
REVANCE THERAPEUTICS, INC.	-22.61%
MACROGENICS, INC.	-77.44%